Specific growth inhibition of ErbB2-expressing human breast cancer cells by genetically modified NK-92 cells

Oncology Reports

Volumn 33, Issue 1, 2015, Pages 95-102

  Liu, Hui ^a   Yang, Bo ^a   Sun, Tingting ^b   Lin, Lin ^a   Hu, Yi ^a   Deng, Muhong ^a   Yang, Junlan ^a   Liu, Tianyi ^a   Li, Jinyu ^a   Sun, Shengjie ^a   Jiao, Shunchang ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Department of Internal Neurology Hainan Branch of 301 General Hospital   (China)

Author keywords

Chimeric antigen receptor; ErbB2; Gene modification; Human breast cancer; Natural killer 92 cells; ScFv antibody

Indexed keywords

CD27 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL4; NATURAL KILLER CELL RECEPTOR NKG2D; ERBB2 PROTEIN, HUMAN;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; BREAST TUMOR; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MDA MB 453 CELL LINE; MOUSE; NATURAL KILLER CELL; NK 92 CELL LINE; NONHUMAN; PROTEIN EXPRESSION; SKBR3 CELL LINE; SURVIVAL TIME; TRANSGENICS; TUMOR VOLUME; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CANCER TRANSPLANTATION; FEMALE; IMMUNOLOGY; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; KILLER CELLS, NATURAL; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; RECEPTOR, ERBB-2; TUMOR BURDEN;

EID: 84916211311     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3548     Document Type: Article

References (36)

1. Yokoyama WM, Kim S and French AR: The dynamic life of natural killer cells. Annu Rev Immunol 22: 405-429, 2004
2. McKenna DH Jr, Sumstad D, Bostrom N, Kadidlo DM, Fautsch S, McNearney S, Dewaard R, McGlave PB, Weisdorf DJ, Wagner JE, McCullough J and Miller JS: Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion 47: 520-528, 2007.
3. Trinchieri G: Biology of natural killer cells. Adv Immunol 47: 187-376, 1989.
4. Smith BR, Rosenthal DS and Ault KA: Natural killer lymphocytes in hairy cell leukemia: presence of phenotypically identifiable cells with defective functional activity. Exp Hematol 13: 189-193, 1985.
5. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, Carreras E, Devergie A, Guglielmi C, Kolb HJ, Niederwieser D: Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation: Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 91: 513-521, 2006.
6. Maki G, Tam YK, Berkahn L and Klingemann HG: Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia. Bone Marrow Transplant 31: 1119-1125, 2003.
7. Tam YK, Miyagawa B, Ho VC and Klingemann HG: Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J Hematother 8: 281-290, 1999.
8. Suck G: Novel approaches using natural killer cells in cancer therapy. Semin Cancer Biol 16: 412-418, 2006.
9. Suck G, Branch DR, Smyth MJ, Miller RG, Vergidis J, Fahim S and Keating A: KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity. Exp Hematol 33: 1160-1171, 2005.
10. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R and Moretta L: Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 19: 197-223, 2001.
11. Liang X, Weigand LU, Schuster IG, Eppinger E, van der Griendt C, Schub A, Leisegang M, Sommermeyer D, Anderl F, Han Y, Ellwart J, Moosmann A, Busch DH, Uckert W, Peschel C and Krackhardt AM: A single TCR alpha-chain with dominant peptide recognition in the allorestricted HER2/neu-specific T cell repertoire. J Immunol 184: 1617-1629, 2010.
12. Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, Sadelain M, Eshhar Z, Rosenberg SA and Morgan RA: A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol 183: 5563-5574, 2009.
13. Zhong XS, Matsushita M, Plotkin J, Riviere I and Sadelain M: Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther 18: 413-420, 2010.
14. Tammana S, Huang X, Wong M, Milone MC, Ma L, Levine BL, June CH, Wagner JE, Blazar BR and Zhou X: 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther 21: 75-86, 2010.
15. Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingemann HG and Wels W: Retargeting of natural killercell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 100: 1265-1273, 2002.
16. Schirrmann T and Pecher G: Tumor-specific targeting of a cell line with natural killer cell activity by asialoglycoprotein receptor gene transfer. Cancer Immunol Immunother 50: 549-556, 2001.
17. Muller T, Uherek C, Maki G, Chow KU, Schimpf A, Klingemann HG, Tonn T and Wels WS: Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother 57: 411-423, 2008.
18. Malmberg KJ, Bryceson YT, Carlsten M, Andersson S, Bjorklund A, Bjorkstrom NK, Baumann BC, Fauriat C, Alici E, Dilber MS and Ljunggren HG: NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy. Cancer Immunol Immunother 57: 1541-1552, 2008.
19. Kruschinski A, Moosmann A, Poschke I, Norell H, Chmielewski M, Seliger B, Kiessling R, Blankenstein T, Abken H and Charo J: Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci USA 105: 17481-17486, 2008.
20. Boissel L, Betancur M, Wels WS, Tuncer H and Klingemann H: Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk Res 33: 1255-1259, 2009.
21. Zhang T, Barber A and Sentman CL: Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Res 66: 5927-5933, 2006.
22. Darcy PK, Kershaw MH, Trapani JA and Smyth MJ: Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma. Eur J Immunol 28: 1663-1672, 1998.
23. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF and Velardi A: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295: 2097-2100, 2002.
24. Tonn T, Becker S, Esser R, Schwabe D and Seifried E: Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 10: 535-544, 2001.
25. Press MF, Cordon-Cardo C and Slamon DJ: Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5: 953-962, 1990.
26. Imai C, Iwamoto S and Campana D: Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106: 376-383, 2005.
27. Tran AC, Zhang D, Byrn R and Roberts MR: Chimeric zetareceptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes. J Immunol 155: 1000-1009, 1995.
28. Roberts MR, Cooke KS, Tran AC, Smith KA, Lin WY, Wang M, Dull TJ, Farson D, Zsebo KM and Finer MH: Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains. J Immunol 161: 375-384, 1998.
29. Tran J and Kung SK: Lentiviral vectors mediate stable and efficient gene delivery into primary murine natural killer cells. Mol Ther 15: 1331-1339, 2007.
30. Piechocki MP, Ho YS, Pilon S and Wei WZ: Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J Immunol 171: 5787-5794, 2003.
31. Cohen JL, Boyer O, Thomas-Vaslin V and Klatzmann D: Suicide gene-mediated modulation of graft-versus-host disease. Leuk Lymphoma 34: 473-480, 1999.
32. Thomis DC, Marktel S, Bonini C, Traversari C, Gilman M, Bordignon C and Clackson T: A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 97: 1249-1257, 2001.
33. Russell JH and Ley TJ: Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 20: 323-370, 2002.
34. Hallett WH and Murphy WJ: Positive and negative regulation of natural killer cells: therapeutic implications. Semin Cancer Biol 16: 367-382, 2006.
35. Uemura A, Takehara T, Miyagi T, Suzuki T, Tatsumi T, Ohkawa K, Kanto T, Hiramatsu N and Hayashi N: Natural killer cell is a major producer of interferon gamma that is critical for the IL-12-induced anti tumor effect in mice. Cancer Immunol Immunother 59: 453-463, 2010.
36. Pegram HJ, Jackson JT, Smyth MJ, Kershaw MH and Darcy PK: Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivo. J Immunol 181: 3449-3455, 2008.